The goal of Insilicomed is to provide engineering analysis solutions to medical technology companies to speed the product development cycle and reduce development costs. We have performed analysis for many companies from major medical device manufacturers to start-ups for applications in heart and ocular disease with a more recent focus on heart failure and its complications.
Through computational models, Insilicomed’s software and databases integrate biological science, medical knowledge and engineering principles. Insilicomed provides innovative predictive simulation tools and the detailed biological properties in a form suitable for our consultants to perform quantitative analyses for you. We rapidly test new medical technology concepts and designs using advanced multi-scale simulations. Insilicomed’s current platform technology models the physical properties of human cardiovascular tissue, including heart muscle and blood vessels, and our expertise in soft tissue mechanics allows us to simulate a wide variety of tissue-device interaction problems.
Insilicomed is a biomedical consulting and clinical products company based in La Jolla, California. The company was founded in 2000 by three prominent University of California San Diego bioengineering research scientists, Drs. Andy McCulloch, Lew Waldman and Jeff Omens. Drs. McCulloch, Waldman and Omens are internationally recognized leaders in cardiovascular mechanics research. Their research and interests in experimental and computational models of cardiac physiology and disease lead to the formation of Insilicomed. The goals of the company are to provide innovative predictive computational analysis services for cardiovascular medical device design, medical imaging, corneal implant and other ocular implant applications.